Abstract
βig-h3/TGF-βi is a secreted protein capable of binding to both extracellular matrix and cells. Human genetic studies recently revealed that in the tgfbi gene encoding for βig-h3, three single nucleotide polymorphisms were significantly associated with type 1 diabetes (T1D) risk. Pancreatic islets express βig-h3 in physiological conditions, but this expression is reduced in β-cell insult in T1D. Since the integrity of islets is destroyed by autoimmune T lymphocytes, we thought to investigate the impact of βig-h3 on T-cell activation. We show here that βig-h3 inhibits T-cell activation markers as well as cytotoxic molecule production as granzyme B and IFN-γ. Furthermore, βig-h3 inhibits early T-cell receptor signaling by repressing the activation of the early kinase protein Lck. Moreover, βig-h3-treated T cells are unable to induce T1D upon transfer in Rag2 knockout mice. Our study demonstrates for the first time that T-cell activation is modulated by βig-h3, an islet extracellular protein, in order to efficiently avoid autoimmune response.
© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Autoimmunity / drug effects*
-
Biomarkers / metabolism
-
Cadaver
-
Cells, Cultured
-
Diabetes Mellitus, Type 1 / drug therapy*
-
Diabetes Mellitus, Type 1 / immunology
-
Diabetes Mellitus, Type 1 / metabolism
-
Diabetes Mellitus, Type 1 / pathology
-
Diabetes Mellitus, Type 2 / drug therapy
-
Diabetes Mellitus, Type 2 / immunology
-
Diabetes Mellitus, Type 2 / metabolism
-
Diabetes Mellitus, Type 2 / pathology
-
Extracellular Matrix Proteins / genetics
-
Extracellular Matrix Proteins / metabolism
-
Extracellular Matrix Proteins / pharmacology*
-
Female
-
Humans
-
Hypoglycemic Agents / metabolism
-
Hypoglycemic Agents / pharmacology*
-
Lymph Nodes / pathology
-
Lymphocyte Activation / drug effects*
-
Lymphocyte Specific Protein Tyrosine Kinase p56(lck) / antagonists & inhibitors
-
Lymphocyte Specific Protein Tyrosine Kinase p56(lck) / metabolism
-
Mice, Inbred C57BL
-
Mice, Inbred NOD
-
Mice, Knockout
-
Protein Kinase Inhibitors / metabolism
-
Protein Kinase Inhibitors / pharmacology
-
Receptors, Antigen, T-Cell / antagonists & inhibitors
-
Receptors, Antigen, T-Cell / metabolism
-
Recombinant Proteins / metabolism
-
Recombinant Proteins / pharmacology
-
Recombinant Proteins / therapeutic use
-
Signal Transduction / drug effects*
-
Specific Pathogen-Free Organisms
-
T-Lymphocytes / drug effects*
-
T-Lymphocytes / immunology
-
T-Lymphocytes / metabolism
-
T-Lymphocytes / pathology
-
Transforming Growth Factor beta / genetics
-
Transforming Growth Factor beta / metabolism
-
Transforming Growth Factor beta / pharmacology*
Substances
-
Biomarkers
-
Extracellular Matrix Proteins
-
Hypoglycemic Agents
-
Protein Kinase Inhibitors
-
Receptors, Antigen, T-Cell
-
Recombinant Proteins
-
Transforming Growth Factor beta
-
betaIG-H3 protein
-
Lymphocyte Specific Protein Tyrosine Kinase p56(lck)